KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Liabilities (2017 - 2025)

Moderna (MRNA) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $285.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 6.74% to $285.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.0 million through Dec 2025, up 6.74% year-over-year, with the annual reading at $285.0 million for FY2025, 6.74% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $285.0 million at Moderna, up from $281.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $285.0 million in Q4 2025, with the low at $1.0 million in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $172.5 million, with a median of $172.5 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities tumbled 54.19% in 2021, then surged 11200.0% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $76.0 million in 2021, then soared by 77.63% to $135.0 million in 2022, then soared by 89.63% to $256.0 million in 2023, then increased by 4.3% to $267.0 million in 2024, then grew by 6.74% to $285.0 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $285.0 million, $281.0 million, and $276.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.